INTRODUCTION
Melatonin is produced in the pineal gland and is released to circulation at night-time. Age-related deterioration in the immune system, which is referred to as immunosenescence, contributes to an increased susceptibility to infection Association between concentration of melatonin, and lipoproteins, LPO, hsCRP, NTproBNP in chronic heart failure patients [5, 20] , as there is a general agreement that the reactive oxygen species (ROS) play an important role in the pathogenesis of cardiac ischemia/reperfusion injury [4, 18] , and Melatonin efficiently interacts with several reactive oxygen species [18] . What is more, in normoglycemic mothers, melatonin increases the ability of colostrum to protect against Escherichia coli and other infections. However, in diabetic mothers, the effects of melatonin are likely limited to antiinflammatory processes, with low superoxidase release and bactericidal activity [15] .
Unfortunately, there is no information about the association of melatonin with lipoproteins level, nor is there information on its relation between the composition and metabolism of HDL particles in chronic heart failure (CHF) patients with NYHA class II and III.
AIM
The aim of the presented study was to examine the relationship between the concentration of melatonin (assessed at 0:200 hrs and 0:700 hrs) and lipid hydroperoxide (LPO) (assessed at 0:200 hrs and 0:700 hrs), and apolipoprotein (apo)AI, apoAII, apoB, hsCRP and NT-proBNP in chronic heart failure (CHF) patients with NYHA class II and III.
MATeRIAL AND MeTHODS
A total of 27 patients who were diagnosed with chronic heart failure (CHF) according to ESC criteria, aged 71 (51-88) years, and 15 apparently normolipidemic healthy individuals as control, were recruited for the study. The CHF patients had undergone treatment in the Department of Internal Disease of the Medical University in Lublin. These patients did not have myocardial infraction in the last 3 months, nor unstable angina pectoris, infections, malignancies or neuropsychiatric disorders [6] . The patients were placed into 3 groups: all patients, patients with NYHA class II (n = 17), and NYHA class III (n = 10) [6] ; however, CHF patients with higher CRP were excluded from the studied groups. The study was conducted in accordance with the guidelines of the Ethics Committee of the Medical University in Lublin, Poland.
Routine laboratory parameters were obtained in serum after a 14-h overnight fasting. Blood was taken from a vein into commercial test tubes. The serum was immediately separated and stored in aliquots at -80°C until use. Using routine laboratory methods, the level of creatinine and NT-proBNP, and lipids were measured on the Cobas Integra analyzer (Germany). Low density lipoprotein cholesterol (LDL-C) was calculated according to the Friedewald formula [8] , while Non-HDL-C was calculated as total cholesterol (TC) minus HDL-C. Serum melatonin concentration at 0:200 hrs and 0:700 hrs was measured using the competitive enzyme immunoassay technique (USCN Life Science Inc., Wuhan, China; Polish distributor -Immuniq). As this assay employs the competitive inhibition enzyme immunoassay technique, an inverse correlation between melatonin concentration in the sample and the assay signal intensity is measured.
ApoAI, apoAII, apoB and high sensitivity C-reactive protein (hsCRP) levels were determined by way of immunonephelometric methods, using the Health Care Diagnostic Product (Siemens GmbH, Germany), on a Dade Behring nephelometer BNII System (Germany). Serum LPO concentration at 0:200 hrs and 0:700 hrs was measured using Cayman's Lipid Hydroperoxide Assay Kit (LPO). This measures the hydroperoxides directly, utilizing the redox reactions with ferrous ions. Hydroperoxides are highly unstable and react readily with ferrous ions to produce ferric ions. The resulting ferric ions are detected by using thiocyanate ion as the chromogen.
Statistical analysis. The data were expressed as medians and minimum-maximum. Shapiro-Wilk's test was used to investigate whether the variables had a normal distribution. The variables with skewed distribution were log 10 transformed. However, the values in the Tables are presented as non-transformed data. The statistical analysis of the obtained results was performed using the nonparametric Kruskal-Wallis test for comparison of patient groups and the reference group. The nonparametric Wilcoxon's t-paired test was used to compare the concentration of LPO at 0:200 hrs and 0:700 hrs in all CHF patients. The relation between the concentration of apoAI, apoAII, apoB, NT-proBNP, hsCRP, LPO at 0:200 hrs and 0:700 hrs, and melatonin at 0:200 hrs and 0:700 hrs was examined by Pearson's correlation analysis. Multiple ridge stepwise forward regression analysis was then used to investigate the relationship between melatonin at 0:200 hrs and 0:700 hrs as an independent variable and apoAI, apoAII, apoB, NT-proBNP, hsCRP, LPO 0:200 hrs and 0:700 hrs concentrations as dependent variables, and for each of the dependent variables, parameters were calculated according to the equation: y = β0 + β1x1 + β2x2 +…+ βnxn. In the model of multiple regression analysis, high correlations between predictor variables result in inadequate regression coefficients. In such cases, multiple ridge stepwise forward regression analysis improves the accuracy of the model. The relationship between the dependent variables is expressed by the coefficient of multiple regression (β), which provides information about the relationship between the dependent and the independent variables. A statistical analysis was performed using the STATISTICA program (StatSoft, Krakow, Poland).
ReSULTS
Concentration of serum lipids, apoAI, apoAII, apoB, NTproBNP, and hsCRP, LPO at 0:200 hrs, LPO at 0:700 hrs, and melatonin at 0:200 hrs and 0:700 hrs, as well as the lipid and lipoprotein ratios are shown in Table 1 . The results of the presented study show that CHF patients had different dyslipidemia, dyslipoproteinemia and atherogenic lipid and lipoprotein ratios and significantly increased concentration of NT-proBNP, hsCRP and LPO at 0:200 hrs and at 0:700 hrs, but not a different level of melatonin at 0:200 hrs and 0:700 hrs, compared to the reference group. However, the nonparametric Wilcoxon's t-paired test demonstrated (p < 0.05) that the concentration of LPO at 0:700 hrs was lower than LPO level at 0:200 hrs in all studied groups. Moreover, patients with NYHA class III had lower lipids, apoAI, apoAII level, and higher hsCRP and NT-proBNP levels than did patients with NYHA class II (Tab. 1). In patients with NYHA class II, Pearson's correlation test showed a significant negative correlation between the concentration of apoAI and LPO at 0:700 hrs (r = -0.678, p = 0.016), and a significant negative correlation between apoAII and LPO levels at 0:700 hrs (r = -0.581, p = 0.048). 
DISCUSSION
Dyslipidemia and the resulting atherosclerosis as a chronic disease remains one of the major causes of death, worldwide. Dyslipidemia and dyslipoproteinemia play a crucial role in cardiovascular diseases through the development of atherosclerosis and the modification of the structure and stability of the cellular membranes [2, 3] . Melatonin has anti-inflammatory and anti-oxidative effects, neutralizes free radicals, increases antioxidative enzymes and glutathione levels, prevents electron leakage from the mitochondrial respiratory chain, acts synergistically with vitamins C, E, and glutathione, reduces levels of pro-inflammatory cytokines, and, therefore, prevents low-density lipoprotein (LDL) oxidation and decreases lipid peroxidation [1, 7, 16] . The results of human and animal studies support the consideration of melatonin as a cardio-protective agent [1, 4, 5, 14, 15, 18, 20] . In addition, melatonin demonstrates a lowering impact on blood pressure, the normalization of lipid profile, and certain anti-inflammatory properties [4, 16, 23, 24] . Recently, Tamura H. et al. [22] has reported that melatonin treatment in periand postmenopausal women elevates serum high density lipoprotein cholesterol levels without influencing total cholesterol levels [22] . However, the mechanisms of beneficial effect of melatonin on these processes remain unknown.
The presented study concerned observations of melatonin and HDL metabolism linkage in all patients with CHF, and with subgroups with NYHA class II and III. CHF patients without acute inflammatory response demonstrated dyslipidemia and dyslipoproteinemia which was characterized by lowered concentrations of HDL-C, apoAI, apoAII. While NT-proBNP, hsCRP and LPO levels at night and during daytime were elevated, the melatonin level did not show such elevation. Moreover, in all CHF patients, as well as in patients with NYHA class II and III, the concentration of LPO at 0:700 hrs was lower than at 0:200 hrs. In addition, a significant negative Pearson's correlation between concentration of apoAI and LPO at 0:700 hrs, and between apoAII and LPO at 0:700 hrs was observed in the group of patients with NYHA class II. However, to have more relevant and essential correlations, multiple ridge stepwise forward regression has been performed. Hence, multiple ridge stepwise regression showed a significant positive relationship between concentration of apoAII and melatonin at 0:200 hrs, but a significant negative relationship between apoAI and LPO levels at 0:700 hrs. These results indicate that melatonin at night exerts a positive effect on apoAII level, and the content of melatonin at 0:200 hrs, apoAI and apoAII, together, have an influence on lowered oxidative stress in CHF patients with NYHA class II.
In this work, Pearson's correlation test and multiple ridge stepwise regression in CHF patients with NYHA III showed a significant positive relationship between concentration of apoAI and melatonin at 0:200 hrs, and between apoAII and melatonin at 0:200 hrs. However, negative relationships were noted between the hsCRP and melatonin (0:200 hrs) and between NT-proBNP and melatonin (0:700 hrs). Moreover, the obtained results suggest that melatonin measured at 0:200 hrs exerts a positive effect on apoAI and apoAII content and HDL composition, which altogether influence the lowering of NT-proBNP during daytime, in patients with advanced CHF without acute inflammation.
In addition, Pearson's correlation test and multiple ridge stepwise regression in all CHF patients showed a significant positive relationship between concentration of apoAII and melatonin at 0:200 hrs, and between apoAII and apoB. Furthermore, a significant negative relationship between concentration of: apoAII and LPO at 0:700 hrs, and between apoAII and NT-proBNP levels, as well as melatonin (0:700 hrs) and hsCRP were noticed. This in turn indicates that melatonin at night may have an influence on rising apoAII, and thus causes a decrease in LPO at 0:700 hrs, as well as NT-proBNP levels in all CHF patients.
The presented results have been confirmed by other researchers [14] , who reported that melatonin clearly slowed lipid peroxidation and apoB carbonylation in LDL, together with a concomitant protection of LDL endogenous antioxidants, i.e., α-tocopherol and β-carotene. Korkmaz A. et al. [12] revealed that the results of human and animal studies support the consideration of melatonin as a cardio-protective agent. These findings are virtually consistent with melatonin being beneficial for cardiovascular physiology, and in the reduction of free radical damage to the myocardium. Considering its low toxicity, melatonin deserves consideration for inclusion in clinical trials attempting to identify molecules with cardiovascular benefits [12] .
Of note, the high anti-oxidant and anti-inflammatory activities of HDL are associated with protection against cardiovascular disease. These activities depend on the protein and lipid composition of HDL and are the greatest in small, dense HDL [10, 11, 19] . These activities are compromised in many pathological states related with inflammation. In addition, the functional deficiency of HDL is intimately associated with changes in the composition of HDL. Research is, thus, being continued to find the best approaches for prevention of the loss or restoration of the antioxidant and anti-inflammatory potential of HDL [2, 10, 11, 19, 21] . Of further note is that the structure and metabolism of HDL are linked to their apoAI and apoAII composition; however, the role of apoAII in the metabolism of HDL is unknown. What is known is that conformational changes of apoAI, the major apolipoprotein of HDL, caused by apoAII in discoidal HDL are confined to two regions of apoAI. In addition, interactions between the two major apolipoproteins in discoidal HDL are site specific. Functional implications of HDL complexes will significantly benefit from such structural information [9] . Of still further note, Apo A-II participates in ABCA1-mediated HDL formation, whereas nascent HDL maturation by LCAT is associated with apo A-I, apo C-I and apo A-IV [13] . Apolipoprotein A-II is a key regulatory factor of HDL metabolism as evidenced from studies with transgenic animals and from clinical outcomes. What is more, HDL metabolism and functionality are closely linked to their major apolipoproteins A-I and A-II, and to certain cargo proteins. However, beyond HDL cholesterol concentrations are needed to identify the discrete HDL particles that are atheroprotective [13] . Recent evidence suggests that the cardioprotective effect of the HDL system may relate chiefly to both the apoAI and apoAII content of HDL particles [17] . A prospective study demonstrated that plasma apoA-II concentrations are an independent factor negatively correlated with the risk of coronary artery disease (CAD) [3] . This challenges the previous notion that apoAII is proatherogenic [3, 17] . Dzida et al. [6] showed in their preliminary results that in patients with advanced CHF (NYHA class III but not NYHA class II), nocturnal melatonin secretion is negatively correlated with NT-proBNP, and suggests that reduced melatonin concentration may result from melatonin synthesis inhibition due to neurohormonal activation [6] . The presented study demonstrates, for the first time, the beneficial effect of melatonin on apoAII and on apoAI composition of HDL particles, and that all these elements are closely related with the functionality of HDL. The presented study also reveals that nocturnal melatonin beneficially changes the content of apoAI and apoAII of HDL particles and the antioxidative, anti-inflammatory function of HDL, but does not have such an influence on NT-proBNP level in patients with NYHA class II. However, in patients with advanced CHF (NYHA class III), nocturnal melatonin has an impact on the increased content of apoAII and apoAI, while these apolipopoteins lower oxidative stress, inflammation, and, together with melatonin, at daytime, decrease the NT-proBNP level.
CONCLUSION
The presented results indicate that nocturnal melatonin exerts a positive effect on the composition of HDL particles which are smaller and denser in patients with CHF. The content of apoAII and apoAI in HDL particles and melatonin level appear to have anti-oxidative and anti-inflammatory effects, and altogether have a beneficial cardio-protective effects in patients with advanced CHF. These relationships, however, need to be confirmed in further studies.
